Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Receivables (2016 - 2025)

Bio-Techne (TECH) has 17 years of Change in Receivables data on record, last reported at -$941000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables fell 251.04% year-over-year to -$941000.0; the TTM value through Dec 2025 reached -$36.5 million, down 283.3%, while the annual FY2025 figure was -$34.1 million, 266.23% down from the prior year.
  • Change in Receivables reached -$941000.0 in Q4 2025 per TECH's latest filing, up from -$22.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $51.6 million in Q1 2022 and bottomed at -$28.9 million in Q2 2025.
  • Average Change in Receivables over 5 years is $2.7 million, with a median of $357500.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: crashed 576.63% in 2022, then soared 19380.43% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $5.7 million in 2021, then rose by 3.5% to $5.9 million in 2022, then plummeted by 180.1% to -$4.7 million in 2023, then skyrocketed by 113.16% to $623000.0 in 2024, then tumbled by 251.04% to -$941000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$941000.0 in Q4 2025, -$22.4 million in Q3 2025, and -$28.9 million in Q2 2025.